Nanogen Pharmaceutical Biotechnology Joint Stock Company
Works in GI & liver · Hematology · Infectious disease · Renal & urogenital · Respiratory · Women's health
Nanogen Pharmaceutical Biotechnology Joint Stock Company is a clinical trial sponsor. It has 1 active clinical trial with 44 planned participants, across 6 therapeutic areas. Since 2021 it has completed 6 trials and stopped 0 early.
Trial track record · since 2021
Pipeline · 1 active trial
| Stage | Trial | Status |
|---|---|---|
Questions about Nanogen Pharmaceutical Biotechnology Joint Stock Company
Nanogen Pharmaceutical Biotechnology Joint Stock Company is lead sponsor of 1 active clinical trial on ClinicalTrials.gov, with 44 planned participants, in GI & liver, Hematology, Infectious disease, Renal & urogenital and other areas. Since 2021 it has completed 6 trials and stopped 0 early.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Nanogen Pharmaceutical Biotechnology Joint Stock Company; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-08-21.
Approve Suite is not affiliated with Nanogen Pharmaceutical Biotechnology Joint Stock Company. Informational only.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.